Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Flputnam Investment Management Co.

Flputnam Investment Management Co. lessened its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 47.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,996 shares of the medical research company's stock after selling 8,852 shares during the quarter. Flputnam Investment Management Co.'s holdings in Edwards Lifesciences were worth $740,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. Private Trust Co. NA boosted its holdings in Edwards Lifesciences by 17.4% in the fourth quarter. Private Trust Co. NA now owns 3,441 shares of the medical research company's stock worth $255,000 after acquiring an additional 510 shares in the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Edwards Lifesciences by 18.8% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,297 shares of the medical research company's stock worth $96,000 after purchasing an additional 205 shares during the period. Financial Security Advisor Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $206,000. Proficio Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $8,456,000. Finally, Oppenheimer Asset Management Inc. lifted its holdings in shares of Edwards Lifesciences by 37.3% during the fourth quarter. Oppenheimer Asset Management Inc. now owns 17,574 shares of the medical research company's stock worth $1,301,000 after purchasing an additional 4,770 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

EW has been the subject of a number of research reports. Morgan Stanley lifted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Barclays lifted their target price on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. The Goldman Sachs Group lifted their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday, December 5th. Finally, Citigroup lifted their target price on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded down $1.19 on Thursday, reaching $71.66. The company's stock had a trading volume of 2,027,583 shares, compared to its average volume of 4,413,320. The company has a market capitalization of $42.27 billion, a P/E ratio of 10.28, a PEG ratio of 4.82 and a beta of 1.10. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a 50-day moving average price of $72.45 and a 200-day moving average price of $70.35. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the transaction, the vice president now owns 23,189 shares of the company's stock, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the transaction, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,739 shares of company stock worth $2,799,104. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.